Key Highlights

  • Revenue growth has consistently beaten plan since the IPO, but adjusted EBITDA fell 10.6% year over year in Q1 2026 and rose just 3.2% in 2025, the gap between sales and profit is the central question.
  • The $150–200 million 2026 Tariff headwind is guided to be front-loaded, so the second-half Margin inflection is the load-bearing assumption in full-year guidance.
  • An open FDA warning letter at the NAMIC site and two recall actions in 2026 add Regulatory Risk that did not exist in the IPO narrative.
  • Medline publishes second-quarter 2026 results before the open on Wednesday 5 August, with a call at 9:30 a.m. ET. It is only the company's third report as a public Business , and it arrives with the Investment case pulling in two directions.

A Third Earnings Report That Matters More Than the First Two

Medline ( Nasdaq :MDLN) publishes second-quarter 2026 results before the open on Wednesday 5 August, with a call at 9:30 a.m. ET. It is only the company's third report as a public business, and it arrives with the investment case pulling in two directions.

The medical-surgical supplier came to the Nasdaq in the biggest US initial public offering of the year, selling 216,034,482 shares at $29 apiece for gross proceeds of roughly $6.26 billion, most of it earmarked to repay senior secured term loans left over from the 2021 buyout by Blackstone, Carlyle and Hellman & Friedman. Since then the Top Line has run ahead of plan while profit has gone backwards, and the quality record has become a live investor question rather than a trade-press footnote.

Flat Since Midsummer, Well Below the High

The shares closed at $39.28 at last closing, up 0.41% on the day, for a market Capitalization of $51.60 billion. That is about 35% above the $29 IPO price, but the recent record is less flattering. The stock closed at $39.44 on 30 June, so July was effectively flat, and choppy with it: a $43.19 close on 2 July, a slide to $37.18 by 22 July, then a partial recovery. Against a 52-week range of $32.82 to $50.88, the shares sit close to a fifth below their high.

They also sit below the $41.00 at which Blackstone, Carlyle, Hellman & Friedman and an Abu Dhabi Investment Authority Subsidiary sold stock. That secondary, launched at 75 million shares, closed at 97.5 million once underwriters took their full option, roughly $4.0 billion of proceeds, none of it to Medline. Buyers of that block are modestly underwater, which is the plainest reading of the market's mood: growth has been accepted, the earnings quality has not.

Scale Is the Product

Medline's advantage is physical: 26 North American production facilities, 69 distribution centers globally, more than 2,000 trucks, over 43,000 employees and a catalog exceeding 335,000 items, supporting next-day delivery to about 95% of US customers. That combination, manufacturer and distributor in one, separates it from pure distributors such as Cardinal Health, McKesson and Owens & Minor.

The financial expression of that structure is two very different segments. In 2025, Medline Brand generated $13.7 billion of sales, up 9.6%, at a 24.3% adjusted EBITDA margin. Supply Chain Solutions, the third-party distribution business, generated $14.7 billion, up 13.2%, at just 5.5%. Growth is coming disproportionately from the low-margin half, which dilutes group profitability even when both halves execute well. Management has guided to about $1 billion of new prime-vendor signings in 2026 after $2.4 billion in 2025, so the mix pressure is a feature of the strategy, not an accident.

Growth Is Not the Problem; Margins Are

Full-year 2025 revenue reached $28.4 billion, up 11.5% with organic growth of 10.5%. Yet Net Income fell 3.6% to $1.2 billion, gross margin slipped to 26.4% from 27.3%, and adjusted EBITDA rose only 3.2% to $3.5 billion. Year-end Debt stood at $12.8 billion against $1.9 billion of cash, with net Leverage at 3.1x and free Cash Flow of $1.3 billion.

The first quarter of 2026 repeated the pattern more sharply. Sales of $7.4 billion rose 10.7% (10.1% organic), but net income dropped 25.8% to $239 million and adjusted EBITDA fell 10.6% to $776 million. Diluted EPS was $0.16, or $0.33 adjusted, and Medline Brand's segment EBITDA margin contracted 330 basis points to 22.1%. Management blamed higher cost of goods including tariffs, spending to onboard new customers, and an IPO-related Bonus . Free cash flow was $316 million and net leverage held at 3.1x on $2.2 billion of cash.

Tariffs are the swing Factor . Medline disclosed a $325 million to $375 million impact for 2025 and projected $150 million to $200 million for 2026, with CFO Mike Drazin telling the first-quarter call that most would land in the first half. Management nonetheless raised full-year Organic Sales guidance to 8.5%–9.5% from 8%–9% while leaving adjusted EBITDA at $3.5 billion to $3.6 billion, a combination that only works if second-half margins recover meaningfully.

Quality Systems Are Now a Public-Market Issue

The FDA issued a warning letter to Medline's NAMIC fluid-management site in Glens Falls, New York, following a December 2025 inspection. The agency cited inadequate corrective action on angiographic control syringes that could disconnect from manifolds, referencing 221 complaints and 177 medical device reports including an air-embolism event, plus visible particulate on Manufacturing equipment and roughly 114 foreign-matter complaints since December 2023. It warned that unresolved violations could bring seizure, injunction or civil money penalties. MedTech Dive reported four serious injuries and no deaths as of 13 March, with excess silicone identified as the cause.

A separate action followed on 9 July, when the company recalled more than 970 lots of convenience kits containing BD ChloraPrep and FREPP applicators whose lidding wrinkles risked microbial contamination. That defect originated with Becton Dickinson, but Medline owns the customer relationship and the logistics of retrieval. Chief executive Jim Boyle told investors in May that recalls to date were "immaterial to our financials." That claim is testable on 5 August.

The Case For, and Against

The bull argument is straightforward: Medline is compounding double-digit revenue growth in a defensive end market, taking share as customers consolidate vendors, and carrying leverage that has fallen to a manageable 3.1x. If the tariff headwind is genuinely front-loaded, adjusted EBITDA should inflect in the second half without any change in commercial momentum.

The bear argument is that two consecutive periods of falling profit on rising sales is a pattern, not noise. Mix shift toward 5.5%-margin distribution is structural. Boyle himself flagged possible softening in hospital utilization on reimbursement cuts and insurance access. And the sponsors, having monetized roughly $4 billion, retain large positions that overhang the register.

Valuation

At $39.28 the shares trade on a trailing P/E of 34.4 and a forward P/E of 25.5, against $29.14 billion of trailing revenue, a price-to-sales ratio near 1.8. Using year-end 2025 debt and first-quarter cash, Enterprise value is roughly $62 billion, or about 17.5 times the midpoint of 2026 adjusted EBITDA guidance. Cardinal Health closed the same session on a forward P/E of 19.89. Medline's premium is defensible on growth and manufacturing margin, but it prices in the second-half recovery rather than waiting for it.

What 5 August Has to Show

Three things will decide how the rest of 2026 is framed: whether adjusted EBITDA grew sequentially from $776 million, whether the tariff drag actually narrowed as promised, and whether the $3.5–$3.6 billion full-year range survives contact with the second quarter. Commentary on remediation at Glens Falls and on hospital volumes into the autumn will carry disproportionate weight for a company with barely seven months of public reporting history.

Upcoming Catalysts

  • Q2 2026 results, before the open, call at 9:30 a.m. ET. First read on whether the tariff drag is easing and whether the $3.5–$3.6 billion adjusted EBITDA guidance holds.
  • Second-half margin recovery, Q3 2026 results, expected late October. Management has guided to sequential EBITDA growth; this is the first clean test of it.
  • Resolution of the March 2026 FDA warning letter. A close-out letter would remove an overhang; escalation would not.
  • Further sponsor selldowns. Blackstone, Carlyle, Hellman & Friedman and ADIA sold 97.5 million shares in March and retain sizeable stakes.

Principal Risks

  • Margin compression from mix. Supply Chain Solutions is growing faster than Medline Brand at a 5.5% adjusted EBITDA margin versus 24.3%, diluting group profitability even when execution is good.
  • Tariff exposure on imported supplies. The 2025 impact was $325–375 million; a re-escalation would overwhelm the modest 2026 guidance.
  • Regulatory and product-quality risk. The FDA warned that unresolved Glens Falls violations could lead to seizure, injunction or civil money penalties.
  • Leverage and Equity overhang. Net debt-funded leverage of 3.1x limits flexibility, and large sponsor holdings can cap rallies.
  • Hospital utilization. Management has flagged possible softening in the second half on reimbursement cuts and insurance access.

Conclusion

Revenue growth has consistently beaten plan since the IPO, but adjusted EBITDA fell 10.6% year over year in Q1 2026 and rose just 3.2% in 2025, the gap between sales and profit is the central question. Set against that: Supply Chain Solutions is growing faster than Medline Brand at a 5.5% adjusted EBITDA margin versus 24.3%, diluting group profitability even when execution is good. The next real test: Q2 2026 results, before the open, call at 9:30 a.m. ET. First read on whether the tariff drag is easing and whether the $3.5–$3.6 billion adjusted EBITDA guidance holds.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.